# Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

> **NCT00313599** · PHASE1 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 28 (actual)

## Conditions studied

- Bladder Cancer
- Brain and Central Nervous System Tumors
- Breast Cancer
- Esophageal Cancer
- Extragonadal Germ Cell Tumor
- Gastric Cancer
- Lung Cancer
- Ovarian Cancer
- Prostate Cancer

## Interventions

- **DRUG:** lapatinib
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00313599
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313599, "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00313599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*